Get All Access for $5/mo

Pfizer Pays $11.6 Billion for Drug-Maker in Its Biggest Deal Since 2016 Pfizer announced it will buy migraine drug maker Biohaven for about $11.6 billion – in cash.

By Madeline Garfinkle Edited by Jessica Thomas

Opinions expressed by Entrepreneur contributors are their own.

In its biggest deal since 2016, Pfizer announced on Tuesday it will buy the drug-maker Biohaven Pharmaceutical Holding for $11.6 billion, bolstering its portfolio ahead of patent losses from some cancer drugs.

The deal will give Pfizer access to Biohaven's approved drug Rimegepant, positioning it as a strong competitor in a crowded market: migraine treatments. Approved in 2020, Rimegepant treats acute migraine attacks and prevents migraine episodes — bringing in sales of $462.5 million in 2021.

This isn't the only billion-dollar deal made by Pfizer in the past year — it's just the biggest. Last year, the company bought Canadian drug developer Trillium Therapeutics for $2.26 billion and drug developer Arena Pharmaceuticals for $6.7 billion.

Related: Pfizer Stock is Ready to be Added to Your Portfolio

Although the company saw tremendous gains from its Covid-19 vaccine, Pfizer expects sales to drop from last year's highs, along with top-selling patents nearing expiration, which could account for the billions of spending on deals to maintain a strong portfolio.

"Investors will like this deal. Given Pfizer's strong balance sheet, this is still a small acquisition, and we would expect more such deals," Wells Fargo analyst Mohit Bansal said in a note.

Pfizer will acquire all the outstanding shares of Biohaven that it does not already own for $148.50 per share in cash, a 78.6% premium to Biohaven's last closing price on Monday.

Related: Buy Pfizer Before the Smart Money Catches On to the Plot

Madeline Garfinkle

News Writer

Madeline Garfinkle is a News Writer at Entrepreneur.com. She is a graduate from Syracuse University, and received an MFA from Columbia University. 

Want to be an Entrepreneur Leadership Network contributor? Apply now to join.

Editor's Pick

Business News

These Companies Offer the Best Work-Life Balance, According to Employees

The ranking is based on Glassdoor ratings and reviews.

Business Ideas

63 Small Business Ideas to Start in 2024

We put together a list of the best, most profitable small business ideas for entrepreneurs to pursue in 2024.

Leadership

Why Your AI Strategy Will Fail Without the Right Talent in Place

Using fractional AI experts through specialized platforms allows companies to access top talent cost-effectively, drive innovation and scale agile strategies for growth.

Growing a Business

Why Business Owners Should Streamline Their Operations Now for Success in 2025

As the holiday season and year-end approach, business owners face heightened operational demands, from inventory management to spend control. By streamlining these processes and partnering with flexible suppliers, businesses can maintain efficiency, meet customer needs and focus on growth while navigating this busy period.

Business News

Here's What the CPI Report Means for Your Wallet, According to JPMorgan and EY Experts

Most experts agree that there will be another rate cut next week.